Nath Bio-Genes (India) Reports Mixed Financial Results for Q2 FY25

Nath Bio-Genes (India), a microcap company in the agri-seeds industry, recently announced its financial results for the quarter ending September 2024. The company’s stock has been given a ‘Sell’ call by MarketsMOJO.

According to the financial report, the company’s score has fallen from 6 to -9 in the last three months, indicating a negative performance for the quarter. However, there are some positive aspects to the financials. The company’s operating cash flow has been consistently growing over the past three years, with the highest amount of Rs 74.59 crore generated annually. Additionally, the net sales for the quarter have shown a growth of 42.62% year on year, indicating a positive sales trend in the near term. The company has also been distributing higher dividends to its shareholders from its profits.

On the other hand, there are some concerning factors in the financial report. The profit before tax less other income has fallen by 56.47% year on year, and the profit after tax has also shown a decline of 46.4% year on year. The interest cost has increased by 33.04% quarter on quarter, indicating increased borrowings by the company. The company’s ability to manage interest payments has also deteriorated, with the operating profit to interest ratio being the lowest in the last five quarters. The earnings per share have also declined, indicating lower profitability for shareholders.

Overall, the financial results for the quarter ending September 2024 show a mix of positive and negative aspects for Nath Bio-Genes. Investors are advised to carefully consider these factors before making any investment decisions.